The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

December 10, 2020 • By Puja Khanna, Dinesh Khanna, Gary Cutter, Jeffrey Foster, Joshua Melnick, Sara Jaafar, Stephanie Biggers, AKM Rahman, Hui-Chen Kuo, Michelle Feese and Kenneth Saag

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Click here to view abstract videoClick here to view visual abstract summary

Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of urate levels and flares, its use is limited due to immunogenicity, leading to infusion reactions.1 Co-administration of an immunomodulatory agent may mitigate this loss of efficacy and concern for drug-related toxicity.

You Might Also Like
  • Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout
  • Phase 3 Studies Evaluate Lesinurad for Gout Treatment
  • Pegloticase Safe & Effective for Patients with Gout on Dialysis

Methods: Patients from 5 rheumatology practices were recruited over 18 months, and randomized (3:1) by site to either to mycophenolate mofetil (MMF) 1 gram twice a day or placebo (PBO) with a run-in of two weeks prior to intravenous pegloticase at 8 mg every 2 weeks (12 infusions). MMF or PBO was given for the first 12 weeks. Inclusion criteria were: a) patients ≥18 years of age who met 2015 ACR/EULAR gout classification criteria and b) chronic refractory gout defined as symptoms inadequately controlled with ULT or contraindication to ULT. Endpoints included: a) proportion of subjects achieving and maintaining a serum urate (sUA) of ≤6 mg/dL at 12 weeks (primary), b) assess six-month durability of immune modulation after discontinuation of MMF at 12 weeks (secondary), and c) adverse events (AEs). Analyses were conducted using SAS (Cary, NC) Version 9.4 with Fisher’s exact test for binary outcomes and Wilcoxon two-sample test for continuous outcomes. Kaplan-Meier estimates and log-rank test were performed to compare survival curves between groups. Hypothesis tests were two tailed, and a P value (P) of <0.05 indicated statistical significance.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Of 42 subjects screened, 35 were randomized, and 32 who received at least one dose of pegloticase were included in modified intention to treat analyses (Table 1: demographics). Nineteen of 22 (86%) in the MMF arm achieved the primary outcome at 12 weeks of sUA ≤6mg/dL, compared with four of 10 (40%) in placebo, P value 0.01. At week 24, sUA response was sustained in 68% of MMF arm vs. 30% in placebo. Estimated rates of AEs per month were similar between groups—MMF (0.3) and placebo (0.4). The MMF arm had higher AEs compared with placebo: musculoskeletal (36% vs. 10%), respiratory (18% vs. 0%) and infections (9% vs. 0%). The placebo arm had a greater percentage of infusion reactions (30% vs. 0%). Figure 1 demonstrates that the percentage of subjects maintaining a sUA <6 mg/dL at 12 weeks was significantly higher (P=0.02) in the MMF arm, and a significant difference (P=0.03) at 24 weeks indicating sustained benefit from MMF.

Conclusion: Short-term concomitant use of MMF with pegloticase was generally well tolerated in our proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. To our knowledge, this is the first randomized controlled trial to demonstrate prolonged efficacy of pegloticase with co-administrations of an immunomodulatory agent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Table 1. Patient demographics for treatment arms of pegloticase with MMF and pegloticase with placebo

Figure 1. Percentage of subjects maintaining SUA less than 6 mg/dL in MMF/pegloticase vs. PBO/pegloticase arms over 24 weeks (Kaplan‐Meier estimates)


Puja Khanna1, Dinesh Khanna1, Gary Cutter2, Jeffrey Foster2, Joshua Melnick3, Sara Jaafar1, Stephanie Biggers2, AKM Rahman2, Hui-Chen Kuo2, Michelle Feese2 and Kenneth Saag4: 1University of Michigan, Ann Arbor; 2University of Alabama at Birmingham; 3University of Alabama at Birmingham, Vestavia Hills; 4University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology.

Disclosures: P. Khanna, Selecta, 5, Dyve, 5; D. Khanna, Bayer, 2, BMS, 2, Horizon, 2, Pfizer, 2, NIH, 2, Immune Tolerance Network, 2, Eicos Sciences Inc, 4, Acceleron,, 5, Actelion,, 5, Abbvie,, 5, Amgen,, 5, Bayer,, 5, Boehringer Ingelheim, 5, CSL Behring, 5, Corbus,, 5, Galapagos,, 5, Genentech/Roche, 5, GSK, 5, Horizon, 5, Merck,, 5, Mitsubishi Tanabe Pharma, 5, Sanofi-Aventis, 5, United Therapeutics, 5, Impact PH, 9, Scleroderma Development, 6, CiviBioPharma/Eicos Sciences Inc, 6; G. Cutter, Horizon Pharmaceuticals, 9, Biogen, 5, Click Therapeutics, 5, Genentech, 5, Gilgamesh Pharmaceuticals, 5, GW Pharmaceuticals, 5, Genzyme, 5, Klein-Buendel Incorporated, 5, Medimmune, 5, Medday, 5, Novartis, 5, Osmotica Pharmaceuticals, 5, Perception Neurosciences, 5, Perception Neurosciences, 5, Recursion Pharmaceuticals, 5, Roche, 5, Somahlution, 5, TG Therapeutics, 5; J. Foster, None; J. Melnick, None; S. Jaafar, None; S. Biggers, None; A. Rahman, None; H. Kuo, None; M. Feese, None; K. Saag, Arthrosi, 5, Horizon Therapeutics plc, 2, 5, Atom Bioscience, 5, LG Pharma, 5, Takeda, 5, Mallinkrodt, 5, SOBI, 2, 5, Shanton, 2.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract number 0952, presented at ACR Convergence 2020.


To cite this abstract in AMA style:

Khanna P, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, Biggers S, Rahman A, Kuo H, Feese M, Saag K. Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/reducing-immunogenicity-of-pegloticase-recipe-with-concomitant-use-of-mycophenolate-mofetil-in-patients-with-refractory-gout-a-phase-ii-double-blind-randomized-controlled-trial.

Filed Under: ACR Convergence, Conditions, Crystal Arthritis, Drug Updates, Meeting Reports Tagged With: ACR Convergence – Gout, ACR Convergence 2020, ACR Convergence 2020 – Gout, Gout

You Might Also Like:
  • Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout
  • Phase 3 Studies Evaluate Lesinurad for Gout Treatment
  • Pegloticase Safe & Effective for Patients with Gout on Dialysis
  • Treatment Options for Severe Refractory Gout When Pegloticase Fails

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)